S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
Undervalued UnitedHealth Group Won’t Be For Long
PayPal’s User Decline Won’t Stop Its Double-Digit Upside

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avinger, Inc. stock logo
AVGR
Avinger
$3.62
-1.9%
$3.30
$2.50
$18.00
$5.76M1.2649,420 shs17,231 shs
ECIA
Encision
$0.70
$0.53
$0.25
$0.75
$8.25M0.37384 shsN/A
LLIT
Lianluo Smart
$0.75
-6.2%
$9.91
$2.76
$17.14
$1.66M0.161.04 million shs335,813 shs
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$1.75
+0.6%
$1.89
$0.97
$5.10
$7.49M0.5930,153 shs7,102 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avinger, Inc. stock logo
AVGR
Avinger
-14.12%+1.94%+26.46%+36.29%-63.20%
ECIA
Encision
0.00%0.00%+52.84%+52.17%+66.67%
LLIT
Lianluo Smart
-6.23%-10.91%-31.01%-15.70%-35.73%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-6.45%-7.94%+0.58%-15.94%-58.15%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avinger, Inc. stock logo
AVGR
Avinger
2.4455 of 5 stars
3.55.00.00.02.70.00.6
ECIA
Encision
N/AN/AN/AN/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
0.9451 of 5 stars
3.53.00.00.01.10.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avinger, Inc. stock logo
AVGR
Avinger
3.00
Buy$5.0038.12% Upside
ECIA
Encision
N/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.00
Buy$10.00471.43% Upside

Current Analyst Ratings

Latest ECIA, AVGR, PSTV, and LLIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2024
Avinger, Inc. stock logo
AVGR
Avinger
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.75N/AN/A($4.53) per share-0.80
ECIA
Encision
$7.35M1.12N/AN/A$0.21 per share3.33
LLIT
Lianluo Smart
$380K4.38N/AN/A($0.59) per share-1.27
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
$4.91M1.53N/AN/A($0.30) per share-5.83

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)
ECIA
Encision
-$320K-$0.04N/AN/A-6.51%-18.97%-10.50%6/20/2024 (Estimated)
LLIT
Lianluo Smart
-$4.45MN/A0.00N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$13.32M-$33.76N/AN/AN/A-271.04%-805.57%-97.73%4/18/2024 (Estimated)

Latest ECIA, AVGR, PSTV, and LLIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2024Q4 2023
Avinger, Inc. stock logo
AVGR
Avinger
$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 million
3/5/2024Q4 2023
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
-$0.78-$0.70+$0.08-$0.70$1.26 million$1.31 million
2/14/2024Q3 2024
ECIA
Encision
N/A-$0.02-$0.02-$0.02N/A$1.58 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
ECIA
Encision
N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/A
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avinger, Inc. stock logo
AVGR
Avinger
N/A
0.63
0.36
ECIA
Encision
0.11
2.55
1.08
LLIT
Lianluo Smart
N/A
2.42
2.17
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
N/A
0.92
0.92

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
ECIA
Encision
8.20%
LLIT
Lianluo Smart
28.75%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
3.28%

Insider Ownership

CompanyInsider Ownership
Avinger, Inc. stock logo
AVGR
Avinger
4.29%
ECIA
Encision
40.87%
LLIT
Lianluo Smart
22.90%
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
2.32%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avinger, Inc. stock logo
AVGR
Avinger
681.59 million1.52 millionNot Optionable
ECIA
Encision
3111.78 million6.96 millionNot Optionable
LLIT
Lianluo Smart
62.21 millionN/ANot Optionable
Plus Therapeutics, Inc. stock logo
PSTV
Plus Therapeutics
204.28 million4.18 millionNot Optionable

ECIA, AVGR, PSTV, and LLIT Headlines

SourceHeadline
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management TeamNeuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
finance.yahoo.com - April 9 at 7:57 AM
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D.
globenewswire.com - April 9 at 7:00 AM
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual ConferencePlus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
finance.yahoo.com - March 27 at 10:29 AM
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell DiagnosticPlus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
finance.yahoo.com - March 25 at 8:51 AM
Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry TailwindsBuy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds
markets.businessinsider.com - March 23 at 7:41 AM
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal MetastasesPlus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
finance.yahoo.com - March 11 at 9:16 AM
Plus Therapeutics Full Year 2023 Earnings: Beats ExpectationsPlus Therapeutics Full Year 2023 Earnings: Beats Expectations
finance.yahoo.com - March 7 at 10:46 AM
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call TranscriptPlus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
finance.yahoo.com - March 7 at 10:46 AM
Q4 2023 Plus Therapeutics Inc Earnings CallQ4 2023 Plus Therapeutics Inc Earnings Call
finance.yahoo.com - March 6 at 6:24 PM
PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023
investorplace.com - March 5 at 10:33 PM
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue EstimatesPlus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
zacks.com - March 5 at 6:36 PM
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsPlus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
globenewswire.com - March 5 at 4:05 PM
IMUNON stock rallies 19% on early results for COVID-19 vaccineIMUNON stock rallies 19% on early results for COVID-19 vaccine
msn.com - February 29 at 1:33 PM
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
finance.yahoo.com - February 27 at 8:49 AM
Plus Therapeutics Inc PSTVPlus Therapeutics Inc PSTV
morningstar.com - February 21 at 6:55 PM
Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0Plus Therapeutics Inc [PSTV] Stock sold by Insider HEDRICK MARC H for $4053.0
knoxdaily.com - January 1 at 10:51 PM
Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024Plus Therapeutics Inc.: Plus Updates Financial and Cash Guidance for 2024
finanznachrichten.de - December 18 at 1:46 PM
Plus Updates Financial and Cash Guidance for 2024Plus Updates Financial and Cash Guidance for 2024
finance.yahoo.com - December 18 at 8:46 AM
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker AnalysesPlus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
finance.yahoo.com - December 12 at 10:20 AM
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), HUTCHMED (HCM) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 29 at 8:56 AM
Fortress Biotech, Plus Therapeutics among healthcare moversFortress Biotech, Plus Therapeutics among healthcare movers
msn.com - November 20 at 2:51 PM
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader WebinarPlus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
finance.yahoo.com - November 20 at 9:51 AM
Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
finance.yahoo.com - November 15 at 10:12 AM
Analysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)Analysts Conflicted on These Healthcare Names: Geron (GERN), Silk Road Medical (SILK) and Plus Therapeutics (PSTV)
markets.businessinsider.com - November 3 at 7:54 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avinger logo

Avinger

NASDAQ:AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.

Encision

OTCMKTS:ECIA
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.

Lianluo Smart

NASDAQ:LLIT
Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.
Plus Therapeutics logo

Plus Therapeutics

NASDAQ:PSTV
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.